The Sanger sequencing market has seen considerable growth owing to its wide applications in DNA sequencing for genetic and molecular research. Sanger sequencing enables DNA and RNA sequencing by catalyzing the polymerization of nucleotide labeled with different fluorescences. It provides accurate, cost-effective, and reliable sequencing to study genomes, genes, DNA samples. The ability to sequence entire human genomes has revolutionized human genetic research and medicine. Sanger sequencing is used to study genetic diseases and disorders, understand human evolution, develop personalized medicine, forensic research and more.
The Global Sanger Sequencing Market is estimated to be valued at US$ 10,130.6 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key players operating in the Global Sanger Sequencing Market are Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ, GenHunter Corporation, GenScript, LGC Biosearch Technologies, Nucleics, Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation, and Source BioScience.
Key Takeaways
Key players: Eurofins Scientific leads the Sanger sequencing market with 15% market share owing to its advanced Sanger sequencing services and instruments for genetic and molecular research applications. Thermo Fisher Scientific Inc. follows with 10% market share driven by its portfolio of Sanger sequencing consumables and instruments.
Key opportunities: Advent of liquid biopsy and non-invasive prenatal testing provides an opportunity for Sanger sequencing players. Integration of sequencing with bioinformatics and cloud computing also present new prospects. Further, growing focus on precision medicine and genetic testing expands growth opportunities.
Global Expansion: Key players are expanding their geographic footprint by establishing manufacturing and R&D facilities across Asia Pacific, Europe, and North America to better serve global customers. Strategic collaborations and partnerships further aid global market penetration.
Market Drivers: Wide applications in genetic disease research and carrier screening as well as requirement for Sanger sequencing as a validation tool for next-generation sequencing drive market growth. Rising funding for genomic and genetic research also spurs demand.
Market Restraints: High costs associated with Sanger sequencing limit its widespread adoption, especially in developing nations. Errors and ambiguity also restrict market potential to some degree.
Segment Analysis
The global Sanger sequencing market is segmented basis type, application and end user. By type, instruments segment dominates the market. Sanger sequencing instruments provide automated and rapid detection of DNA and RNA sequences. Continuous technological advancements have increased throughput and sequencing speed of latest generation instruments which has boosted their adoption rate across research laboratories and clinical settings.
By application, drug discovery segment holds the largest share. Sanger sequencing finds widespread application in identification of genetic variations, nucleotide polymorphisms and genome sequencing which aids drug target discovery and validation studies. It is commonly employed during preclinical and clinical phases of drug development process to study efficacy and safety of candidate molecules.
Global Analysis
Regionally, North America commands the leading position in global Sanger sequencing market. Higher R&D investments and vast funding for genomics research from both private and public organizations have augmented regional market growth. Increased adoption of NGS techniques will continue to provide lucrative opportunities. Europe holds the second largest revenue share and growth will be predominantly driven by emerging countries in Asia Pacific and Latin America. With ongoing initiatives to establish genomic centers and expansion of healthcare infrastructure, developing countries are anticipated to witness fastest gains over the coming years.
Get more insights on Sanger Sequencing Market
Comments
0 comment